Nutex Health (NUTX) Financials

$130.18 +15.55 (+13.57%)

Closing price 05/5/2025 04:00 PM Eastern

Extended Trading

$129.82 -0.36 (-0.28%)

As of 05:01 AM Eastern

Annual Income Statements for Nutex Health

This table shows Nutex Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-425	-46	52
Consolidated Net Income / (Loss)	-433	-43	95
Net Income / (Loss) Continuing Operations	-433	-43	95
Total Pre-Tax Income	-420	-48	110
Total Operating Income	-407	-32	131
Total Gross Profit	15	35	196
Total Revenue	219	248	480
Operating Revenue	219	248	480
Total Cost of Revenue	124	123	133
Operating Cost of Revenue	124	123	133
Total Operating Expenses	502	157	217
Selling, General & Admin Expense	87	106	174
Depreciation Expense	13	18	19
Other Operating Expenses / (Income)	0.19	3.05	17
Impairment Charge	398	30	7.08
Restructuring Charge	3.89	0.04	0.00
Total Other Income / (Expense), net	-13	-17	-21
Interest Expense	12	16	20
Other Income / (Expense), net	-0.56	-0.40	-0.94
Income Tax Expense	13	-5.07	14
Net Income / (Loss) Attributable to Noncontrolling Interest	-7.96	2.36	43
Basic Earnings per Share	($100.36)	($10.39)	$10.25
Weighted Average Basic Shares Outstanding	650.93M	745.43M	5.53M
Diluted Earnings per Share	($100.36)	($10.39)	$9.71
Weighted Average Diluted Shares Outstanding	650.93M	745.43M	5.53M
Weighted Average Basic & Diluted Shares Outstanding	650.93M	745.43M	5.53M

This table shows Nutex Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-412	-15	-5.15	-3.48	-5.54	-32	-0.36	-0.36	-8.79	62
Consolidated Net Income / (Loss)	-423	-11	-6.92	-4.27	-4.52	-28	-0.54	3.01	-7.17	100
Net Income / (Loss) Continuing Operations	-423	-11	-6.92	-4.27	-4.52	-28	-0.54	3.01	-7.17	100
Total Pre-Tax Income	-431	-8.85	-7.83	-5.08	-4.87	-31	-0.15	3.90	-2.58	109
Total Operating Income	-429	-5.78	-4.45	-0.36	-0.82	-26	1.45	5.30	9.66	114
Total Gross Profit	-24	-3.32	4.85	9.65	7.07	13	10	23	22	142
Total Revenue	28	54	56	59	63	70	67	76	79	258
Operating Revenue	28	54	56	59	63	70	67	76	79	258
Total Cost of Revenue	32	61	30	28	32	32	32	32	34	35
Operating Cost of Revenue	32	61	30	28	32	32	32	32	34	35
Total Operating Expenses	426	-1.67	31	31	31	64	34	39	35	109
Selling, General & Admin Expense	23	21	25	27	26	28	29	28	28	89
Depreciation Expense	4.33	3.27	3.99	4.17	4.75	4.68	4.19	4.53	4.97	5.28
Other Operating Expenses / (Income)	0.08	-26	2.12	0.25	0.05	0.64	0.05	-0.06	1.96	15
Total Other Income / (Expense), net	-2.77	-3.07	-3.39	-4.72	-4.04	-4.57	-1.60	-1.39	-12	-5.63
Interest Expense	3.40	2.86	3.14	4.84	4.10	4.24	4.44	5.05	5.38	5.05
Other Income / (Expense), net	0.63	-0.21	-0.25	0.12	0.05	-0.33	2.84	3.66	-6.86	-0.58
Income Tax Expense	-8.54	1.81	-0.91	-0.82	-0.34	-3.00	0.39	0.89	4.58	8.61
Net Income / (Loss) Attributable to Noncontrolling Interest	-11	4.09	-1.77	-0.79	1.02	3.91	-0.18	3.37	1.62	38
Basic Earnings per Share	($0.62)	($0.02)	($0.12)	($0.79)	($1.25)	($0.04)	($0.01)	($0.07)	($1.72)	$11.16
Weighted Average Basic Shares Outstanding	649.77M	650.93M	656.56M	661.90M	670.78M	745.43M	49.72M	5.07M	5.44M	5.53M
Diluted Earnings per Share	($0.62)	($0.02)	($0.12)	($0.79)	($1.25)	($0.04)	($0.01)	($0.07)	($1.72)	$11.16
Weighted Average Diluted Shares Outstanding	649.77M	650.93M	656.56M	661.90M	670.78M	745.43M	49.72M	5.07M	5.44M	5.53M
Basic & Diluted Earnings per Share	-	($0.02)	-	-	-	($0.04)	-	-	-	$11.16
Weighted Average Basic & Diluted Shares Outstanding	649.77M	650.93M	656.56M	661.90M	670.78M	745.43M	49.72M	5.07M	5.44M	5.53M
Cash Dividends to Common per Share	-	-	-	-	-	-	-	-	-	$0.50

This table details how cash moves in and out of Nutex Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-1.86	-12	22
Net Cash From Operating Activities	51	1.26	23
Net Cash From Continuing Operating Activities	51	1.71	23
Net Income / (Loss) Continuing Operations	-433	-43	95
Consolidated Net Income / (Loss)	-433	-43	95
Depreciation Expense	13	18	19
Non-Cash Adjustments To Reconcile Net Income	401	35	74
Changes in Operating Assets and Liabilities, net	69	-7.37	-165
Net Cash From Investing Activities	-4.34	-11	-2.67
Net Cash From Continuing Investing Activities	-4.34	-11	-2.67
Purchase of Property, Plant & Equipment	-15	-9.50	-2.30
Acquisitions	13	-0.70	0.00
Other Investing Activities, net	-2.42	-1.04	-0.36
Net Cash From Financing Activities	-48	-2.27	1.09
Net Cash From Continuing Financing Activities	-48	-2.27	1.09
Repayment of Debt	-9.03	-22	-17
Payment of Dividends	-51	-5.21	-6.44
Issuance of Debt	3.44	24	9.28
Issuance of Common Equity	0.00	0.00	9.20
Other Financing Activities, net	8.69	0.30	5.73

This table details how cash moves in and out of Nutex Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-11	-2.37	-1.42	-0.08	-5.93	-4.82	8.00	11	6.10	-3.33
Net Cash From Operating Activities	-7.30	4.51	1.05	0.01	1.97	-1.78	3.05	13	6.79	0.05
Net Cash From Continuing Operating Activities	-7.30	4.51	1.05	0.01	1.97	-1.32	3.05	13	6.79	0.05
Net Income / (Loss) Continuing Operations	-423	-11	-6.92	-4.27	-4.52	-28	-0.54	3.01	-7.17	100
Consolidated Net Income / (Loss)	-423	-11	-6.92	-4.27	-4.52	-28	-0.54	3.01	-7.17	100
Depreciation Expense	4.33	3.27	3.99	4.17	4.75	4.68	4.19	4.53	4.97	5.28
Non-Cash Adjustments To Reconcile Net Income	399	0.89	2.00	1.22	0.38	31	-2.29	4.11	9.28	63
Changes in Operating Assets and Liabilities, net	13	11	1.97	-1.11	1.37	-9.61	1.70	1.61	-0.29	-168
Net Cash From Investing Activities	-5.89	7.88	-5.42	-3.07	-3.62	0.87	-0.73	-1.27	-0.27	-0.40
Net Cash From Continuing Investing Activities	-5.89	7.88	-5.42	-3.07	-3.62	0.87	-0.73	-1.27	-0.27	-0.40
Purchase of Property, Plant & Equipment	-5.89	7.88	-4.38	-3.07	-2.88	0.83	-0.73	-0.56	-0.62	-0.40
Net Cash From Financing Activities	2.21	-15	2.95	2.98	-4.28	-3.91	5.69	-1.19	-0.42	-2.99
Net Cash From Continuing Financing Activities	2.21	-15	2.95	2.98	-4.28	-3.91	5.69	-1.19	-0.42	-2.99
Repayment of Debt	-1.00	-3.31	-3.15	-7.80	-3.91	-6.70	-5.95	-2.24	-3.18	-5.30
Payment of Dividends	-2.14	-1.26	-1.54	-1.15	-1.65	-0.88	-0.48	-1.38	-1.80	-2.78
Issuance of Debt	5.26	-9.28	7.60	11	1.28	4.02	2.92	2.13	3.10	1.13
Other Financing Activities, net	0.09	-0.90	0.03	0.62	-	-0.35	0.00	0.30	1.46	3.96

This table presents Nutex Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	432	398	655
Total Current Assets	98	91	292
Cash & Equivalents	34	22	44
Accounts Receivable	58	63	236
Inventories, net	3.53	3.39	2.85
Prepaid Expenses	1.87	2.68	10.00
Plant, Property, & Equipment, net	82	81	78
Total Noncurrent Assets	252	226	285
Goodwill	17	17	14
Intangible Assets	21	21	16
Noncurrent Deferred & Refundable Income Taxes	-	0.00	7.99
Other Noncurrent Operating Assets	213	188	247
Total Liabilities & Shareholders' Equity	432	398	655
Total Liabilities	311	319	453
Total Current Liabilities	55	58	141
Short-Term Debt	15	14	18
Accounts Payable	28	25	9.61
Accrued Expenses	6.24	13	25
Current Deferred & Payable Income Tax Liabilities	-	0.00	26
Other Current Liabilities	5.92	5.90	62
Total Noncurrent Liabilities	257	261	313
Long-Term Debt	23	26	22
Capital Lease Obligations	204	214	259
Noncurrent Deferred & Payable Income Tax Liabilities	10	5.15	0.00
Other Noncurrent Operating Liabilities	19	15	31
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	120	79	202
Total Preferred & Common Equity	96	61	146
Total Common Equity	96	61	146
Common Stock	459	471	503
Retained Earnings	-363	-409	-357
Noncontrolling Interest	24	18	56

This table presents Nutex Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	435	430	436	480	404	422	438
Total Current Assets	108	89	92	90	100	114	120
Cash & Equivalents	37	33	33	27	30	41	47
Accounts Receivable	63	52	52	55	66	65	66
Inventories, net	3.21	3.49	2.45	2.68	2.98	2.76	2.26
Prepaid Expenses	4.38	0.83	4.86	5.65	1.63	5.07	4.28
Plant, Property, & Equipment, net	72	77	83	85	81	79	78
Total Noncurrent Assets	255	264	261	304	223	230	240
Goodwill	17	17	17	18	17	14	14
Intangible Assets	22	21	20	22	20	16	16
Other Noncurrent Operating Assets	216	226	224	265	186	200	211
Total Liabilities & Shareholders' Equity	435	430	436	480	404	422	438
Total Liabilities	302	321	328	375	324	340	359
Total Current Liabilities	44	48	57	67	60	72	68
Short-Term Debt	6.62	13	19	23	12	17	14
Accounts Payable	21	19	20	24	24	24	17
Accrued Expenses	10	10	12	15	18	23	30
Other Current Liabilities	5.59	5.61	5.66	5.73	5.95	7.57	7.32
Total Noncurrent Liabilities	258	273	271	307	264	269	291
Long-Term Debt	25	25	25	19	26	22	27
Capital Lease Obligations	205	221	-	264	213	227	241
Noncurrent Deferred & Payable Income Tax Liabilities	8.83	9.54	8.73	8.49	5.05	2.80	3.40
Other Noncurrent Operating Liabilities	20	17	237	16	20	17	20
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	133	110	108	105	80	82	80
Total Preferred & Common Equity	110	93	93	90	63	63	60
Total Common Equity	110	93	93	90	63	63	60
Common Stock	469	461	465	467	472	473	479
Retained Earnings	-359	-368	-372	-377	-409	-410	-419
Noncontrolling Interest	22	17	16	15	17	19	19

This table displays calculated financial ratios and metrics derived from Nutex Health's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-33.85%	12.93%	93.80%
EBITDA Growth	-314.90%	96.30%	1,119.47%
EBIT Growth	-331.75%	92.10%	503.07%
NOPAT Growth	-268.12%	92.19%	609.81%
Net Income Growth	-356.78%	89.97%	319.40%
EPS Growth	-356.78%	89.97%	193.46%
Operating Cash Flow Growth	-70.82%	-97.52%	1,742.79%
Free Cash Flow Firm Growth	-113.39%	98.08%	-473.21%
Invested Capital Growth	5.69%	-5.01%	47.10%
Revenue Q/Q Growth	-30.23%	6.88%	64.37%
EBITDA Q/Q Growth	-24.08%	-424.77%	1,769.47%
EBIT Q/Q Growth	-23.68%	-175.20%	1,344.22%
NOPAT Q/Q Growth	-23.78%	-178.53%	1,764.22%
Net Income Q/Q Growth	-22.50%	-64.67%	393.97%
EPS Q/Q Growth	-22.50%	-64.67%	228.27%
Operating Cash Flow Q/Q Growth	-45.30%	-83.33%	8.58%
Free Cash Flow Firm Q/Q Growth	38.40%	90.37%	-152.99%
Invested Capital Q/Q Growth	-1.17%	-18.92%	45.70%
Profitability Metrics	-	-	-
Gross Margin	7.03%	14.04%	40.89%
EBITDA Margin	-179.68%	-5.89%	30.97%
Operating Margin	-185.41%	-12.83%	27.22%
EBIT Margin	-185.67%	-12.99%	27.02%
Profit (Net Income) Margin	-197.33%	-17.53%	19.85%
Tax Burden Percent	103.12%	89.55%	86.81%
Interest Burden Percent	103.07%	150.72%	84.63%
Effective Tax Rate	0.00%	0.00%	13.19%
Return on Invested Capital (ROIC)	-89.20%	-6.96%	29.46%
ROIC Less NNEP Spread (ROIC-NNEP)	-180.00%	-16.59%	22.05%
Return on Net Nonoperating Assets (RNNOA)	-188.28%	-36.59%	38.35%
Return on Equity (ROE)	-277.48%	-43.55%	67.81%
Cash Return on Invested Capital (CROIC)	-94.73%	-1.82%	-8.66%
Operating Return on Assets (OROA)	-98.54%	-7.75%	24.62%
Return on Assets (ROA)	-104.73%	-10.46%	18.09%
Return on Common Equity (ROCE)	-187.28%	-34.35%	50.15%
Return on Equity Simple (ROE_SIMPLE)	-451.42%	-70.66%	65.10%
Net Operating Profit after Tax (NOPAT)	-285	-22	113
NOPAT Margin	-129.79%	-8.98%	23.63%
Net Nonoperating Expense Percent (NNEP)	90.80%	9.63%	7.42%
Return On Investment Capital (ROIC_SIMPLE)	-78.59%	-6.67%	22.60%
Cost of Revenue to Revenue	56.50%	49.48%	27.67%
SG&A Expenses to Revenue	39.51%	42.80%	36.22%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	228.91%	63.35%	45.11%
Earnings before Interest and Taxes (EBIT)	-407	-32	130
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-394	-15	149
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	12.88	1.96	1.18
Price to Tangible Book Value (P/TBV)	21.41	5.06	1.47
Price to Revenue (P/Rev)	5.63	0.49	0.36
Price to Earnings (P/E)	0.00	0.00	3.30
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	30.28%
Enterprise Value to Invested Capital (EV/IC)	4.47	1.19	1.06
Enterprise Value to Revenue (EV/Rev)	6.69	1.50	1.01
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	3.26
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	3.73
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	4.27
Enterprise Value to Operating Cash Flow (EV/OCF)	28.98	295.10	20.91
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	2.01	3.22	1.49
Long-Term Debt to Equity	1.88	3.04	1.40
Financial Leverage	1.05	2.21	1.74
Leverage Ratio	2.65	4.16	3.75
Compound Leverage Factor	2.73	6.27	3.17
Debt to Total Capital	66.78%	76.28%	59.77%
Short-Term Debt to Total Capital	4.19%	4.25%	3.58%
Long-Term Debt to Total Capital	62.59%	72.03%	56.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	6.76%	5.29%	11.07%
Common Equity to Total Capital	26.47%	18.43%	29.16%
Debt to EBITDA	-0.61	-17.45	2.02
Net Debt to EBITDA	-0.53	-15.94	1.72
Long-Term Debt to EBITDA	-0.58	-16.47	1.90
Debt to NOPAT	-0.85	-11.44	2.64
Net Debt to NOPAT	-0.73	-10.45	2.26
Long-Term Debt to NOPAT	-0.80	-10.80	2.49
Altman Z-Score	-1.28	-0.76	1.13
Noncontrolling Interest Sharing Ratio	32.51%	21.12%	26.05%
Liquidity Ratios	-	-	-
Current Ratio	1.79	1.56	2.08
Quick Ratio	1.69	1.45	1.99
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-302	-5.81	-33
Operating Cash Flow to CapEx	345.86%	13.23%	1,004.98%
Free Cash Flow to Firm to Interest Expense	-24.20	-0.36	-1.67
Operating Cash Flow to Interest Expense	4.05	0.08	1.16
Operating Cash Flow Less CapEx to Interest Expense	2.88	-0.51	1.05
Efficiency Ratios	-	-	-
Asset Turnover	0.53	0.60	0.91
Accounts Receivable Turnover	2.53	4.09	3.21
Inventory Turnover	39.04	35.39	42.57
Fixed Asset Turnover	1.87	3.03	6.02
Accounts Payable Turnover	5.48	4.64	7.61
Days Sales Outstanding (DSO)	144.04	89.24	113.63
Days Inventory Outstanding (DIO)	9.35	10.31	8.58
Days Payable Outstanding (DPO)	66.55	78.66	47.95
Cash Conversion Cycle (CCC)	86.83	20.89	74.25
Capital & Investment Metrics	-	-	-
Invested Capital	328	311	458
Invested Capital Turnover	0.69	0.77	1.25
Increase / (Decrease) in Invested Capital	18	-16	147
Enterprise Value (EV)	1,467	371	484
Market Capitalization	1,235	121	172
Book Value per Share	$0.15	$0.09	$26.92
Tangible Book Value per Share	$0.09	$0.04	$21.50
Total Capital	362	333	502
Total Debt	242	254	300
Total Long-Term Debt	227	240	282
Net Debt	208	232	256
Capital Expenditures (CapEx)	15	9.50	2.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	24	25	126
Debt-free Net Working Capital (DFNWC)	58	47	170
Net Working Capital (NWC)	43	33	152
Net Nonoperating Expense (NNE)	148	21	18
Net Nonoperating Obligations (NNO)	208	232	256
Total Depreciation and Amortization (D&A)	13	18	19
Debt-free, Cash-free Net Working Capital to Revenue	10.96%	9.98%	26.25%
Debt-free Net Working Capital to Revenue	26.58%	18.86%	35.33%
Net Working Capital to Revenue	19.66%	13.14%	31.59%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($100.50)	($10.50)	$10.25
Adjusted Weighted Average Basic Shares Outstanding	4.34M	4.97M	5.53M
Adjusted Diluted Earnings per Share	($100.50)	($10.50)	$9.71
Adjusted Weighted Average Diluted Shares Outstanding	4.34M	4.97M	5.53M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	4.34M	4.97M	5.53M
Normalized Net Operating Profit after Tax (NOPAT)	-3.20	-1.06	120
Normalized NOPAT Margin	-1.46%	-0.43%	24.91%
Pre Tax Income Margin	-191.36%	-19.58%	22.87%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-32.60	-1.97	6.51
NOPAT to Interest Expense	-22.79	-1.36	5.69
EBIT Less CapEx to Interest Expense	-33.77	-2.55	6.39
NOPAT Less CapEx to Interest Expense	-23.96	-1.95	5.57
Payout Ratios	-	-	-
Dividend Payout Ratio	-11.84%	-12.01%	6.76%
Augmented Payout Ratio	-11.84%	-12.01%	6.76%

This table displays calculated financial ratios and metrics derived from Nutex Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-75.93%	-63.88%	-28.81%	1.51%	120.89%	29.68%	19.75%	29.12%	25.62%	269.77%
EBITDA Growth	-642.68%	-103.69%	-102.37%	24.48%	100.94%	-701.28%	1,325.01%	243.28%	95.40%	645.70%
EBIT Growth	-661.69%	-108.33%	-117.47%	-1,065.89%	99.82%	-341.86%	191.45%	3,848.23%	464.65%	529.22%
NOPAT Growth	-505.44%	-105.59%	-110.72%	73.70%	99.81%	-352.42%	132.61%	1,709.99%	1,276.62%	674.57%
Net Income Growth	-667.71%	-115.48%	-127.88%	82.22%	98.93%	-159.99%	92.16%	170.56%	-58.38%	460.75%
EPS Growth	-788.89%	-115.48%	-127.88%	82.22%	98.93%	-159.99%	92.16%	170.56%	-37.60%	28,000.00%
Operating Cash Flow Growth	-130.11%	-90.29%	-97.06%	-99.93%	126.96%	-139.42%	190.00%	107,538.69%	244.93%	103.01%
Free Cash Flow Firm Growth	-18,760.86%	90.90%	-1,036.19%	191.75%	90.56%	91.37%	113.10%	-129.71%	244.41%	-2,117.77%
Invested Capital Growth	367.29%	5.69%	419.67%	-83.74%	15.79%	-5.01%	-10.40%	156.37%	-18.14%	47.10%
Revenue Q/Q Growth	-51.08%	89.20%	4.85%	4.61%	6.45%	11.07%	-3.18%	12.79%	3.57%	226.95%
EBITDA Q/Q Growth	-13,520.63%	99.36%	74.55%	667.89%	1.22%	-647.79%	138.91%	59.14%	-42.39%	1,429.78%
EBIT Q/Q Growth	-1,729,945.58%	98.60%	21.68%	94.91%	-221.33%	-3,346.96%	116.21%	108.75%	-68.74%	3,957.42%
NOPAT Q/Q Growth	-30,998.14%	98.65%	23.08%	91.84%	-126.52%	-3,083.64%	105.54%	302.65%	65.55%	1,454.63%
Net Income Q/Q Growth	-1,662.26%	97.48%	35.06%	38.36%	-6.04%	-512.55%	98.04%	654.89%	-338.02%	1,495.24%
EPS Q/Q Growth	-1,966.67%	97.48%	35.06%	38.36%	-6.04%	-512.55%	98.04%	654.89%	-2,357.14%	748.84%
Operating Cash Flow Q/Q Growth	-141.34%	161.71%	-76.65%	-98.83%	15,878.07%	-190.24%	271.76%	334.63%	-48.80%	-99.21%
Free Cash Flow Firm Q/Q Growth	16.69%	96.13%	-1,165.63%	324.86%	-108.57%	96.46%	2,020.92%	-609.74%	141.67%	-154.35%
Invested Capital Q/Q Growth	-55.04%	-1.17%	2.57%	-64.33%	220.23%	-18.92%	-3.26%	2.07%	2.24%	45.70%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	-83.51%	-6.18%	8.61%	16.37%	11.27%	18.97%	15.06%	29.65%	27.82%	54.98%
EBITDA Margin	-1,492.23%	-5.06%	-1.23%	6.67%	6.34%	-31.28%	12.57%	17.73%	9.86%	46.16%
Operating Margin	-1,509.70%	-10.76%	-7.89%	-0.62%	-1.31%	-37.53%	2.15%	6.96%	12.26%	44.33%
EBIT Margin	-1,507.48%	-11.15%	-8.33%	-0.41%	-1.22%	-38.00%	6.36%	11.78%	3.55%	44.11%
Profit (Net Income) Margin	-1,489.38%	-19.84%	-12.29%	-7.24%	-7.21%	-39.78%	-0.80%	3.96%	-9.09%	38.81%
Tax Burden Percent	98.02%	120.39%	88.37%	83.95%	92.97%	90.24%	354.98%	77.10%	277.66%	92.07%
Interest Burden Percent	100.79%	147.77%	166.92%	2,126.30%	633.60%	116.00%	-3.56%	43.58%	-92.14%	95.55%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.90%	0.00%	7.93%
Return on Invested Capital (ROIC)	-1,649.15%	-5.17%	-5.41%	-0.20%	-0.59%	-20.35%	1.22%	6.93%	7.18%	50.90%
ROIC Less NNEP Spread (ROIC-NNEP)	-1,774.26%	-9.23%	-8.90%	-4.58%	-2.24%	-24.63%	0.53%	6.03%	1.76%	48.78%
Return on Net Nonoperating Assets (RNNOA)	-1,687.30%	-9.65%	-10.64%	-1.24%	-4.52%	-54.33%	1.24%	7.52%	4.89%	84.84%
Return on Equity (ROE)	-3,336.44%	-14.83%	-16.06%	-1.44%	-5.12%	-74.68%	2.46%	14.45%	12.06%	135.74%
Cash Return on Invested Capital (CROIC)	-243.65%	-94.73%	-289.14%	72.38%	-16.86%	-1.82%	5.29%	-94.38%	18.00%	-8.66%
Operating Return on Assets (OROA)	-1,830.10%	-5.92%	-6.38%	-0.12%	-0.62%	-22.68%	3.95%	7.57%	2.26%	40.19%
Return on Assets (ROA)	-1,808.12%	-10.53%	-9.41%	-2.19%	-3.66%	-23.74%	-0.50%	2.54%	-5.78%	35.36%
Return on Common Equity (ROCE)	-2,980.04%	-10.01%	-14.47%	-1.32%	-4.32%	-58.91%	2.02%	11.80%	9.82%	100.38%
Return on Equity Simple (ROE_SIMPLE)	-319.72%	0.00%	-501.52%	-480.20%	-29.32%	0.00%	-58.78%	-47.45%	-53.62%	0.00%
Net Operating Profit after Tax (NOPAT)	-300	-4.05	-3.11	-0.25	-0.57	-18	1.01	4.09	6.76	105
NOPAT Margin	-1,056.79%	-7.53%	-5.52%	-0.43%	-0.92%	-26.27%	1.50%	5.37%	8.58%	40.82%
Net Nonoperating Expense Percent (NNEP)	125.12%	4.05%	3.49%	4.38%	1.65%	4.28%	0.70%	0.91%	5.42%	2.12%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.12%	-	-	-	-5.49%	-	-	-	20.96%
Cost of Revenue to Revenue	111.06%	113.86%	53.01%	47.73%	51.55%	46.23%	47.92%	42.04%	42.94%	13.46%
SG&A Expenses to Revenue	80.98%	38.37%	44.03%	45.39%	42.05%	40.28%	43.65%	36.35%	35.46%	34.47%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	1,498.65%	-3.11%	54.88%	52.88%	49.76%	91.29%	49.93%	50.99%	44.80%	42.21%
Earnings before Interest and Taxes (EBIT)	-428	-5.99	-4.69	-0.24	-0.77	-26	4.29	8.96	2.80	114
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-424	-2.72	-0.69	3.93	3.98	-22	8.48	13	7.77	119
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.82	12.88	7.10	2.99	1.49	1.96	1.13	0.47	1.82	1.18
Price to Tangible Book Value (P/TBV)	13.56	21.41	12.00	5.02	2.66	5.06	2.77	0.91	3.58	1.47
Price to Revenue (P/Rev)	3.10	5.63	3.35	1.40	0.58	0.49	0.28	0.11	0.38	0.36
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.30
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	30.28%
Enterprise Value to Invested Capital (EV/IC)	3.60	4.47	2.68	2.54	1.11	1.19	1.03	0.89	1.16	1.06
Enterprise Value to Revenue (EV/Rev)	3.81	6.69	4.59	1.54	1.85	1.50	1.20	0.99	1.25	1.01
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	95.39	0.00	0.00	66.02	45.77	3.26
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.73
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.27
Enterprise Value to Operating Cash Flow (EV/OCF)	12.93	28.98	56.61	0.00	56.81	295.10	95.17	16.63	17.07	20.91
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.98	0.00	0.00	18.36	0.00	5.79	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.78	2.01	2.37	0.41	2.92	3.22	3.14	3.25	3.53	1.49
Long-Term Debt to Equity	1.73	1.88	2.25	0.23	2.70	3.04	2.99	3.04	3.36	1.40
Financial Leverage	0.95	1.05	1.20	0.27	2.02	2.21	2.36	1.25	2.78	1.74
Leverage Ratio	2.51	2.65	2.81	1.94	3.85	4.16	4.40	4.51	4.97	3.75
Compound Leverage Factor	2.53	3.92	4.69	41.23	24.39	4.83	-0.16	1.97	-4.58	3.58
Debt to Total Capital	64.03%	66.78%	70.33%	29.14%	74.48%	76.28%	75.85%	76.46%	77.92%	59.77%
Short-Term Debt to Total Capital	1.80%	4.19%	3.56%	12.70%	5.60%	4.25%	3.67%	4.92%	3.84%	3.58%
Long-Term Debt to Total Capital	62.23%	62.59%	66.77%	16.44%	68.88%	72.03%	72.18%	71.54%	74.08%	56.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	5.98%	6.76%	4.58%	10.22%	3.64%	5.29%	5.13%	5.54%	5.35%	11.07%
Common Equity to Total Capital	29.99%	26.47%	25.09%	60.64%	21.88%	18.43%	19.02%	18.01%	16.72%	29.16%
Debt to EBITDA	-0.74	-0.61	-0.61	-0.11	68.18	-17.45	-46.50	64.08	35.42	2.02
Net Debt to EBITDA	-0.63	-0.53	-0.53	-0.03	62.20	-15.94	-40.95	54.27	29.52	1.72
Long-Term Debt to EBITDA	-0.72	-0.58	-0.58	-0.06	63.05	-16.47	-44.25	59.96	33.67	1.90
Debt to NOPAT	-1.03	-0.85	-0.84	-0.14	-38.33	-11.44	-13.87	-18.82	-41.33	2.64
Net Debt to NOPAT	-0.87	-0.73	-0.74	-0.04	-34.97	-10.45	-12.22	-15.94	-34.45	2.26
Long-Term Debt to NOPAT	-1.00	-0.80	-0.80	-0.08	-35.45	-10.80	-13.20	-17.61	-39.29	2.49
Altman Z-Score	-1.57	1.78	0.57	-0.14	-0.35	-0.71	-0.49	-0.46	-0.32	1.05
Noncontrolling Interest Sharing Ratio	10.68%	32.51%	9.91%	8.35%	15.59%	21.12%	17.89%	18.34%	18.58%	26.05%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.45	1.79	1.85	1.60	1.34	1.56	1.68	1.59	1.77	2.08
Quick Ratio	2.28	1.69	1.76	1.48	1.21	1.45	1.60	1.48	1.68	1.99
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-561	-22	-275	618	-53	-1.87	36	-184	76	-42
Operating Cash Flow to CapEx	-123.96%	0.00%	24.04%	0.40%	68.45%	0.00%	416.03%	2,375.63%	1,100.12%	13.53%
Free Cash Flow to Firm to Interest Expense	-164.84	-7.58	-87.49	127.55	-12.92	-0.44	8.10	-36.31	14.21	-8.23
Operating Cash Flow to Interest Expense	-2.15	1.57	0.34	0.00	0.48	-0.42	0.69	2.62	1.26	0.01
Operating Cash Flow Less CapEx to Interest Expense	-3.88	4.33	-1.06	-0.63	-0.22	-0.22	0.52	2.51	1.15	-0.07
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.21	0.53	0.77	0.30	0.51	0.60	0.62	0.64	0.64	0.91
Accounts Receivable Turnover	9.86	2.53	7.33	2.67	3.93	4.09	4.41	4.71	4.82	3.21
Inventory Turnover	0.00	39.04	0.00	56.25	51.39	35.39	38.69	49.46	52.75	42.57
Fixed Asset Turnover	8.70	1.87	5.10	2.62	2.94	3.03	3.28	3.41	3.57	6.02
Accounts Payable Turnover	12.87	5.48	13.12	6.86	6.72	4.64	5.81	5.87	6.45	7.61
Days Sales Outstanding (DSO)	37.02	144.04	49.82	136.90	92.96	89.24	82.70	77.55	75.65	113.63
Days Inventory Outstanding (DIO)	0.00	9.35	0.00	6.49	7.10	10.31	9.43	7.38	6.92	8.58
Days Payable Outstanding (DPO)	28.37	66.55	27.81	53.18	54.33	78.66	62.85	62.15	56.57	47.95
Cash Conversion Cycle (CCC)	8.66	86.83	22.01	90.21	45.73	20.89	29.28	22.78	26.00	74.25
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	332	328	336	120	384	311	301	308	314	458
Invested Capital Turnover	1.56	0.69	0.98	0.46	0.65	0.77	0.81	1.29	0.84	1.25
Increase / (Decrease) in Invested Capital	261	18	272	-618	52	-16	-35	188	-70	147
Enterprise Value (EV)	1,196	1,467	901	304	428	371	310	274	364	484
Market Capitalization	975	1,235	657	277	134	121	71	30	110	172
Book Value per Share	$0.17	$0.15	$0.14	$0.14	$0.14	$0.09	$0.08	$1.26	$11.93	$26.92
Tangible Book Value per Share	$0.11	$0.09	$0.08	$0.08	$0.08	$0.04	$0.03	$0.66	$6.05	$21.50
Total Capital	368	362	369	153	411	333	331	348	361	502
Total Debt	236	242	260	44	306	254	251	266	282	300
Total Long-Term Debt	229	227	247	25	283	240	239	249	268	282
Net Debt	199	208	227	12	279	232	221	226	235	256
Capital Expenditures (CapEx)	5.89	-7.88	4.38	3.07	2.88	-0.83	0.73	0.56	0.62	0.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)	34	24	21	21	19	25	23	19	19	126
Debt-free Net Working Capital (DFNWC)	70	58	54	54	46	47	53	59	66	170
Net Working Capital (NWC)	64	43	41	35	23	33	40	42	52	152
Net Nonoperating Expense (NNE)	123	6.61	3.81	4.01	3.95	9.41	1.56	1.08	14	5.18
Net Nonoperating Obligations (NNO)	199	208	227	12	279	232	221	226	235	256
Total Depreciation and Amortization (D&A)	4.33	3.27	4.00	4.17	4.75	4.68	4.19	4.53	4.97	5.28
Debt-free, Cash-free Net Working Capital to Revenue	10.73%	10.96%	10.73%	10.78%	8.10%	9.98%	8.74%	6.72%	6.58%	26.25%
Debt-free Net Working Capital to Revenue	22.38%	26.58%	27.44%	27.37%	19.68%	18.86%	20.34%	21.51%	22.64%	35.33%
Net Working Capital to Revenue	20.27%	19.66%	20.76%	17.55%	9.75%	13.14%	15.64%	15.30%	17.89%	31.59%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($97.50)	($3.00)	($1.50)	($1.50)	($1.50)	($6.00)	($0.10)	($0.07)	($1.72)	$11.16
Adjusted Weighted Average Basic Shares Outstanding	4.33M	4.34M	4.38M	4.41M	4.47M	4.97M	4.97M	5.07M	5.44M	5.53M
Adjusted Diluted Earnings per Share	($97.50)	($3.00)	($1.50)	($1.50)	($1.50)	($6.00)	($0.10)	($0.07)	($1.72)	$11.16
Adjusted Weighted Average Diluted Shares Outstanding	4.33M	4.34M	4.38M	4.41M	4.47M	4.97M	4.97M	5.07M	5.44M	5.53M
Adjusted Basic & Diluted Earnings per Share	$0.00	($3.00)	$0.00	$0.00	$0.00	($6.00)	$0.00	$0.00	$0.00	$11.16
Adjusted Weighted Average Basic & Diluted Shares Outstanding	4.33M	4.34M	4.38M	4.41M	4.47M	4.97M	4.97M	5.07M	5.44M	5.53M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-4.05	-3.11	-0.25	-0.54	-18	1.01	9.23	7.06	105
Normalized NOPAT Margin	-75.30%	-7.53%	-5.52%	-0.43%	-0.87%	-26.27%	1.50%	12.13%	8.96%	40.82%
Pre Tax Income Margin	-1,519.46%	-16.48%	-13.91%	-8.62%	-7.76%	-44.08%	-0.23%	5.13%	-3.27%	42.15%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-125.80	-2.09	-1.49	-0.05	-0.19	-6.25	0.97	1.77	0.52	22.49
NOPAT to Interest Expense	-88.19	-1.41	-0.99	-0.05	-0.14	-4.32	0.23	0.81	1.26	20.81
EBIT Less CapEx to Interest Expense	-127.53	0.66	-2.89	-0.68	-0.89	-6.05	0.80	1.66	0.41	22.41
NOPAT Less CapEx to Interest Expense	-89.92	1.34	-2.38	-0.69	-0.84	-4.13	0.06	0.70	1.14	20.74
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-26.22%	-11.84%	-4.29%	-1.37%	-21.21%	-12.01%	-11.23%	-14.75%	-14.00%	6.76%
Augmented Payout Ratio	-26.22%	-11.84%	-4.29%	-1.37%	-21.21%	-12.01%	-11.23%	-14.75%	-14.00%	6.76%

Frequently Asked Questions About Nutex Health's Financials

When does Nutex Health's fiscal year end?

According to the most recent income statement we have on file, Nutex Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Nutex Health's net income changed over the last 2 years?

Nutex Health's net income appears to be on a downward trend, with a most recent value of $95.27 million in 2024, falling from -$432.74 million in 2022. The previous period was -$43.42 million in 2023. View Nutex Health's forecast to see where analysts expect Nutex Health to go next.

What is Nutex Health's operating income?

Nutex Health's total operating income in 2024 was $130.62 million, based on the following breakdown:

Total Gross Profit: $196.26 million
Total Operating Expenses: $216.52 million

How has Nutex Health revenue changed over the last 2 years?

Over the last 2 years, Nutex Health's total revenue changed from $219.29 million in 2022 to $479.95 million in 2024, a change of 118.9%.

How much debt does Nutex Health have?

Nutex Health's total liabilities were at $453.43 million at the end of 2024, a 42.1% increase from 2023, and a 45.6% increase since 2022.

How much cash does Nutex Health have?

In the past 2 years, Nutex Health's cash and equivalents has ranged from $22.00 million in 2023 to $43.58 million in 2024, and is currently $43.58 million as of their latest financial filing in 2024.

How has Nutex Health's book value per share changed over the last 2 years?

Over the last 2 years, Nutex Health's book value per share changed from 0.15 in 2022 to 26.92 in 2024, a change of 18,148.4%.

Related Companies

This page (NASDAQ:NUTX) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nutex Health (NUTX) Financials

Frequently Asked Questions About Nutex Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nutex Health (NUTX) Financials

Annual Income Statements for Nutex Health

Quarterly Income Statements for Nutex Health

Annual Cash Flow Statements for Nutex Health

Quarterly Cash Flow Statements for Nutex Health

Annual Balance Sheets for Nutex Health

Quarterly Balance Sheets for Nutex Health

Annual Metrics and Ratios for Nutex Health

Quarterly Metrics and Ratios for Nutex Health

Frequently Asked Questions About Nutex Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools